Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Holdings Raised by Trexquant Investment LP

Trexquant Investment LP boosted its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMABFree Report) by 417.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 76,585 shares of the company’s stock after buying an additional 61,785 shares during the quarter. Trexquant Investment LP owned approximately 0.18% of Y-mAbs Therapeutics worth $417,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. BlackRock Inc. raised its holdings in shares of Y-mAbs Therapeutics by 6.4% during the 1st quarter. BlackRock Inc. now owns 2,945,094 shares of the company’s stock valued at $34,986,000 after purchasing an additional 177,734 shares in the last quarter. Polar Capital Holdings Plc raised its holdings in shares of Y-mAbs Therapeutics by 108.9% during the 1st quarter. Polar Capital Holdings Plc now owns 2,877,671 shares of the company’s stock valued at $34,187,000 after purchasing an additional 1,500,000 shares in the last quarter. State Street Corp raised its holdings in shares of Y-mAbs Therapeutics by 58.5% during the 1st quarter. State Street Corp now owns 2,308,782 shares of the company’s stock valued at $27,428,000 after purchasing an additional 852,112 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Y-mAbs Therapeutics by 4,676.0% during the 4th quarter. Millennium Management LLC now owns 1,128,702 shares of the company’s stock valued at $5,508,000 after purchasing an additional 1,105,069 shares in the last quarter. Finally, Acadian Asset Management LLC raised its holdings in shares of Y-mAbs Therapeutics by 24.0% during the 3rd quarter. Acadian Asset Management LLC now owns 811,261 shares of the company’s stock valued at $4,420,000 after purchasing an additional 157,173 shares in the last quarter. Hedge funds and other institutional investors own 45.45% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on YMAB. HC Wainwright raised their price target on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Canaccord Genuity Group raised their target price on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Wedbush reiterated an “outperform” rating and issued a $18.00 target price (up from $12.00) on shares of Y-mAbs Therapeutics in a research note on Monday, February 12th. Finally, BMO Capital Markets raised their target price on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a research note on Monday, March 4th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of “Hold” and an average price target of $16.57.

Read Our Latest Stock Report on YMAB

Insider Activity at Y-mAbs Therapeutics

In related news, SVP Vignesh Rajah sold 1,711 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $16.53, for a total value of $28,282.83. Following the sale, the senior vice president now owns 33,889 shares of the company’s stock, valued at $560,185.17. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 50,000 shares of the business’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $6.61, for a total value of $330,500.00. Following the transaction, the insider now directly owns 265,032 shares in the company, valued at $1,751,861.52. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Vignesh Rajah sold 1,711 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $16.53, for a total transaction of $28,282.83. Following the completion of the transaction, the senior vice president now owns 33,889 shares in the company, valued at $560,185.17. The disclosure for this sale can be found here. Insiders have sold a total of 101,711 shares of company stock valued at $687,783 over the last quarter. 21.50% of the stock is owned by company insiders.

Y-mAbs Therapeutics Trading Down 0.1 %

Shares of Y-mAbs Therapeutics stock opened at $17.62 on Monday. The firm’s 50-day simple moving average is $12.71 and its 200-day simple moving average is $8.12. Y-mAbs Therapeutics, Inc. has a twelve month low of $2.70 and a twelve month high of $20.90.

About Y-mAbs Therapeutics

(Free Report)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma.

Featured Articles

Institutional Ownership by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.